Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
Tags :Boris Wenger
Mérieux Equity Partners, France (MxEP) has agreed to invest EUR 40 million into Swixx Biopharma, Switzerland (Swixx), taking a minority position. SIX listed HBM Healthcare Investments who had invested in Swixx in 2017, will co-invest alongside
The team was led by Markus Vischer (Partner, Corporate/M&A - pictured) and Samuel Lieberherr (Managing Associate, Corporate/M&A) and further included Michael Kündig (Senior Associate, Corporate/M&A), Reto Jacobs (Partner,
Baker McKenzie advised UBS in all legal, regulatory and competition law aspects of the transaction. The team was led by Ansgar Schott (Financial Services - pictured left), Pascal Richard (pictured second left) and Petra Hanselmann (
Baker McKenzie advised G+D in all legal, regulatory and competition law aspects of the transaction. The team was led by Kilian Perroulaz (M&A and Transaction Tax) and Pascal Richard (M&A)
CSL enters partnership with Thermo Fisher Scientific, a global biotechnology company with a dynamic portfolio of life-saving medicines.
The Swiss Similasan Group, which develops and produces homeopathic products and natural cosmetics since 1980, decided to establish a strategic alliance with France-based Laboratoires Thea in the area of eye care products
Deutsche Börse Group’s post-trade services provider Clearstream and Ubs have agreed on a partnership in the investment fund services business segment.
